A Cohort Study in Newly Diagnosed MZL

Sponsor
Fudan University
Study ID
NCT06449885
Status
Recruiting
Apply to this trial

Conditions

  • Marginal Zone Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • patients receive optimal treatment or follow-up according to the characteristics of the disease — OTHER
    Patients with MZL who are eligible for enrollment will be evaluated by the investigator and the enrolled patients will receive long-term follow-up after collecting medical history information, biological samples, and oncology data according to the study protocol. This study does not specify a detailed treatment modality, and patients receive optimal treatment or follow-up according to the characteristics of the disease.

Study Details

Describe the clinical features, diagnosis and treatment status, disease course and primary outcomes of different subtypes of marginal zone B-cell lymphoma (MZL), observe the therapeutic efficacy and safety of different treatment modalities.

Key Dates

First listed
Jun 10, 2024
Start date
May 30, 2024
Status verified
Nov 2025
Primary completion
Jun 30, 2029
Completion
Jun 30, 2034

Study Design

Enrollment
2,500 participants (estimated)

Arms

  • Arm: Newly diagnosed marginal zone lymphoma
    Newly diagnosed marginal zone lymphoma，including Mucosa-associated lymphoid tissue (MALT) lymphoma, spleen MZL, and lymph node MZL, as well as primary cutaneous MZL, and pediatric NMZL.

Primary Outcome Measure

Progression-free survival [ Time Frame: assessed up to 10 years ]

Central Contacts

Related Studies